{'fraction_non_alphanumeric': 0.036322360953461974, 'fraction_numerical': 0.0022701475595913734, 'mean_word_length': 5.94488188976378, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Improvement in insulin sensitivity without concomitant changes in body composition and cardiovascular risk markers following fixed administration of a very low growth hormone (GH) dose in adults with severe GH deficiency

Objective  Untreated GH‐deficient adults are predisposed to insulin resistance and excess cardiovascular mortality. We showed previously that short‐term treatment with a very low GH dose (LGH) enhanced insulin sensitivity in young healthy adults. The present study was therefore designed to explore the hypothesis that LGH, in contrast to the standard GH dose titrated to normalize serum IGF‐I levels (SGH), may have differing effects on insulin sensitivity, body composition, and cardiovascular risk markers [lipid profile, C‐reactive protein (CRP), interleukin‐6 (IL‐6), tumour necrosis factor‐α (TNF‐α) and adiponectin] in adults with severe GH deficiency.